DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Toronto Dominion Bank

Toronto Dominion Bank raised its position in DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,522 shares of the medical device company’s stock after acquiring an additional 6,227 shares during the quarter. Toronto Dominion Bank owned approximately 0.05% of DexCom worth $13,711,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. ORG Partners LLC boosted its holdings in DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after purchasing an additional 498 shares during the period. Envestnet Portfolio Solutions Inc. increased its stake in shares of DexCom by 2.0% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 27,268 shares of the medical device company’s stock worth $3,092,000 after buying an additional 547 shares during the period. Swedbank AB raised its holdings in DexCom by 5.0% in the second quarter. Swedbank AB now owns 185,575 shares of the medical device company’s stock valued at $21,040,000 after acquiring an additional 8,795 shares in the last quarter. Blue Trust Inc. lifted its stake in DexCom by 128.8% in the second quarter. Blue Trust Inc. now owns 881 shares of the medical device company’s stock worth $100,000 after acquiring an additional 496 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its holdings in DexCom by 14.4% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock worth $183,336,000 after acquiring an additional 203,043 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DXCM shares. Citigroup lifted their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Wells Fargo & Company increased their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Price Performance

DexCom stock opened at $77.19 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business has a 50 day simple moving average of $73.58 and a 200-day simple moving average of $84.99. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a market capitalization of $30.15 billion, a PE ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.